Eli Lilly and Company (NYSE:LLY) Shares Bought by Spartan Planning & Wealth Management

Spartan Planning & Wealth Management raised its stake in Eli Lilly and Company (NYSE:LLY) by 74.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,282 shares of the company’s stock after acquiring an additional 547 shares during the period. Eli Lilly and Company accounts for approximately 0.8% of Spartan Planning & Wealth Management’s portfolio, making the stock its 23rd largest position. Spartan Planning & Wealth Management’s holdings in Eli Lilly and Company were worth $747,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $26,000. Tidemark LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $29,000. Core Wealth Advisors Inc. boosted its stake in shares of Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the period. Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $36,000. Finally, Frank Rimerman Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $37,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of Eli Lilly and Company stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the transaction, the insider now owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the transaction, the insider now owns 98,556,247 shares of the company’s stock, valued at approximately $79,752,700,634.87. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the transaction, the executive vice president now directly owns 25,428 shares in the company, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold a total of 567,826 shares of company stock worth $475,376,178 in the last quarter. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Up 0.7 %

Shares of NYSE LLY opened at $885.01 on Tuesday. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $892.20. The firm’s 50 day moving average price is $788.10 and its 200 day moving average price is $721.39. The firm has a market cap of $841.12 billion, a P/E ratio of 130.34, a price-to-earnings-growth ratio of 1.92 and a beta of 0.36. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter last year, the business earned $1.62 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were issued a $1.30 dividend. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.59%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analysts Set New Price Targets

Several research analysts recently issued reports on LLY shares. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday. Citigroup increased their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Argus increased their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Bank of America increased their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, Truist Financial increased their price target on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $787.53.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.